Novo Nordisk clears fresh gains in Copenhagen, shares backed by new analyst targets

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:58.

Novo Nordisk A/S (DK0062498333) starts the new week with its B shares trading higher on Nasdaq Copenhagen, with the latest print around 304.60 Danish kroner. MarketScreener quotes a gain of roughly 1.6 percent for Monday’s session in Copenhagen, underlining the persistent strength of the large-cap healthcare name.

What analysts say this week

Analysts have recently reiterated a constructive stance on Novo Nordisk, with Nordea Bank rating the stock “Buy” and highlighting the company’s obesity drug growth pipeline. Berenberg lifted its price target for Novo Nordisk to 325 kroner while maintaining a “Buy” rating, citing expected Wegovy-driven revenue expansion and strong demand for GLP-1 therapies in key markets.

German houses have taken a more differentiated view: Deutsche Bank keeps its recommendation at “Hold” with a 290-kroner target, pointing to valuation after the strong run of the S&P 500-listed American depositary receipts. On German trading venues such as Tradegate, Novo Nordisk shares most recently changed hands around 40 euros, reflecting the positive Copenhagen close in local-currency terms.

Consensus picture and recent news

Across major broker platforms, a clear majority of covering analysts currently rate Novo Nordisk as a “Buy” or equivalent, while a smaller group stays neutral, according to the consensus data compiled by MarketScreener. The average target price in these overviews stands materially above the latest Copenhagen quote, underlining the expectation of continued earnings growth from the obesity and diabetes franchise.

On the legal front, Reuters reported that a South African court granted Novo Nordisk’s request to halt local Ozempic copies, strengthening the company’s position in protecting its diabetes brand in emerging markets. In parallel, the Novo Nordisk Foundation recently announced an investment of 450 million Danish kroner into cardiometabolic drug discovery, underscoring the strategic focus on expanding beyond diabetes and obesity into adjacent therapeutic areas.

How Novo Nordisk makes its money

Economically, Novo Nordisk generates most of its revenue from diabetes and obesity care, with GLP-1 products such as Ozempic for type 2 diabetes and Wegovy for chronic weight management as key growth drivers. Additional business lines include insulin therapies and treatments for rare blood and endocrine disorders, giving the group a broad portfolio in the global biopharmaceutical sector.

Where the shares trade today

The Novo Nordisk B shares (DK0062498333) most recently traded on Nasdaq Copenhagen at about 304.60 Danish kroner on 2026-06-23, 11:30, while German listings on venues such as Tradegate reflected an equivalent price level of roughly 40 euros in early trading.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a professional advisor.